secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2024-06-05T23:59:59+00:00
Accession:  0001493152-24-022732
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharmaceuticals replaces auditor: Mazars USA succeeded by Forvis Mazars, LLP after Mazars USA merger
--------------------------------------------------------------------------------

- Mazars USA resigned as auditor effective June 1, 2024, as substantially all partners/employees joined Forvis, LLP (renamed Forvis Mazars, LLP).
- Forvis Mazars appointed as new independent registered public accounting firm, effective same date, approved by Audit Committee and Board.
- No disagreements or reportable events between company and Mazars USA during past two fiscal years and interim period.
- No prior consultations with Forvis Mazars regarding accounting principles or audit opinions before appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224022732/0001493152-24-022732-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224022732/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-022732

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer